MUTATIONAL SPECTRUM OF THE P53 GENE IN HUMAN SMALL-CELL LUNG-CANCER AND RELATIONSHIP TO CLINICOPATHOLOGICAL DATA

被引:0
|
作者
LOHMANN, D
PUTZ, B
REICH, U
BOHM, J
PRAUER, H
HOFLER, H
机构
[1] GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST PATHOL,MUNICH,GERMANY
[2] TECH UNIV MUNICH,INST PATHOL,W-8000 MUNICH 2,GERMANY
[3] TECH UNIV MUNICH,DEPT SURG,W-8000 MUNICH 2,GERMANY
来源
AMERICAN JOURNAL OF PATHOLOGY | 1993年 / 142卷 / 03期
关键词
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The spectrum of p53 gene mutations was determined in formalin-fixed, paraffin-embedded samples of small-cell lung cancer derived from 28 patients. By direct sequencing of exons 5, 7, and 8, including their flanking intron sequences, 18 mutations were identified in 17 tumors (61%), and in all but two of these the wild type allele was lost. In 8 cases, the mutation detected in the tumor was absent from the corresponding normal tissue, indicating that these mutations were somatically acquired. In two patients, identical mutations were found in the primary tumor and corresponding metastases. In a further case, an intrapulmonary metastasis did not show the mutation detected in the primary tumor. The local distribution of the mutations resembled that reported in non-small cell lung cancer and gave no indication of distinct hot spot regions. G-to-T transversions were the predominant type of mutation, reflecting a possible genotoxic influence of carcinogens contained in tobacco smoke. Mutations were equally distributed among tumors with intermediate and oat cell histology and did not show a significant association to age and gender of the patients. Also, no significant relationship was observed between the presence of a mutation and tumor stage (T, N, M) or survival. However, transitions at CpG dinucleotides were restricted to tumors without detectable metastases at the time of biopsy, whereas all other mutations occurred in metastasing small cell lung cancer.
引用
收藏
页码:907 / 915
页数:9
相关论文
共 50 条
  • [21] CHEMOTHERAPY OF SMALL-CELL LUNG-CANCER
    HANSEN, HH
    KRISTJANSEN, PEG
    EUROPEAN JOURNAL OF CANCER, 1991, 27 (03) : 342 - 349
  • [22] MANAGEMENT OF SMALL-CELL LUNG-CANCER
    JOHNSON, BE
    CLINICS IN CHEST MEDICINE, 1993, 14 (01) : 173 - 187
  • [23] SURGERY OF SMALL-CELL LUNG-CANCER
    GRESCHUCHNA, D
    MAASSEN, W
    ATEMWEGS-UND LUNGENKRANKHEITEN, 1986, 12 (01) : 19 - 21
  • [24] BIOLOGY OF SMALL-CELL LUNG-CANCER
    CARNEY, DN
    LANCET, 1992, 339 (8797): : 843 - 846
  • [25] ULTRASTRUCTURE OF SMALL-CELL LUNG-CANCER
    YAGUBOV, AS
    KATZ, VA
    DUMANYAN, DG
    VOPROSY ONKOLOGII, 1986, 32 (05) : 36 - 43
  • [26] SMALL-CELL LUNG-CANCER AND TOPOISOMERASES
    GIACCONE, G
    ANTICANCER RESEARCH, 1994, 14 (1B) : 269 - 276
  • [27] CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER
    RUFFIE, P
    LECHEVALIER, T
    BULLETIN DU CANCER, 1987, 74 (05) : 531 - 540
  • [28] NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG-CANCER - RADIOGRAPHIC AND CLINICOPATHOLOGICAL ANALYSIS
    ISHIDA, T
    INOUE, T
    HAMATAKE, M
    KOHDONO, S
    FUKUYAMA, Y
    TATEISHI, M
    SUGIO, K
    SUGIMACHI, K
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1994, 4 (01) : 75 - 80
  • [29] SURGERY FOR SMALL-CELL LUNG-CANCER
    MULLER, LC
    SALZER, GM
    FROMMHOLD, H
    DENZ, H
    HUBER, H
    LANCET, 1989, 2 (8672): : 1152 - 1152
  • [30] CARBOPLATIN IN SMALL-CELL LUNG-CANCER
    GATZEMEIER, U
    HOSSFELD, DK
    NEUHAUSS, R
    RECK, M
    ACHTERRATH, W
    LENAZ, L
    SEMINARS IN ONCOLOGY, 1991, 18 (01) : 8 - 16